In short. What would have to be true for the claim to hold, and which of the materials grouped under it could even in principle meet it.
Key points
- A treatment cannot rebuild tissue if what was injected is no longer there.
- Where cells do not survive, the claim has to be restated as a claim about a transient signal, and a transient signal is a much weaker basis for a structural change than the word regenerative implies.
The regeneration claim is specific enough to be examined. Setting out what would have to be true for it to hold makes it possible to see which of the materials grouped under the word could meet it and which could not.
What rebuilding requires
For tissue to be rebuilt, cells have to be present, to survive, to take on the function of the tissue they are in, to integrate with what surrounds them, and to persist long enough for the result to matter. Each requirement is separate and each can fail. A treatment that satisfies none of them cannot be rebuilding anything, whatever the mechanism described around it.
The survival problem
This is the step where most of the claim fails. Most cells delivered by injection into tissue do not remain there, and the survival of injected cells is poor. That finding is not specific to aesthetics; it is a general difficulty in cell-based treatment, and it is the reason scientific scepticism about these products is not merely regulatory caution. If the cells do not survive, then anything that follows must be explained by a signal they left behind rather than by their presence, and the claim shifts from rebuilding to provoking.
Rebuilding requires something to do the rebuilding
A treatment cannot rebuild tissue if what was injected is no longer there. Where cells do not survive, the claim has to be restated as a claim about a transient signal, and a transient signal is a much weaker basis for a structural change than the word regenerative implies.
Which materials could in principle meet it
A material that persists in the tissue and provokes a durable response is at least consistent with part of the claim, and one material in this group is approved for a named indication on that basis. A preparation that is reabsorbed after a short period cannot meet it in the same way, because nothing remains to do the rebuilding. And a product that is not authorised, has no long-term data and is supported mainly by laboratory findings has not met it and cannot be assessed against it.
What the mechanism claim is actually doing
It is doing the work that outcome evidence would do if it existed. A mechanism is a reason to run a study, not a substitute for one, and the reasoning here is presented as though the study had been run and returned a result. The distinction between the two is the most useful thing a reader can carry into this subject.
Three things the mechanism cannot establish
- That injected cells survive in useful numbers, when most do not.
- That anything a person would notice changes, over any period.
- That the material has been assessed by anybody for the use being proposed.
The mechanism is a hypothesis. Where a page presents it as a finding, that presentation is the claim, and it is the claim this review declines to repeat.
Frequently asked questions
What would have to happen for tissue to be rebuilt?
Cells would have to survive in the tissue, take on the function of the cells around them, integrate with what is already there, and persist. Each of those is a separate requirement, and the survival step alone is where most of these treatments fail, because most injected cells do not remain.
Why is cell survival the decisive question?
Because a treatment described as rebuilding tissue requires the cells to be present to do the rebuilding. If they do not survive, the rebuilding has to be explained by something else, and the mechanism collapses back onto a signal or a response rather than the cells themselves.
Which materials could in principle meet the claim?
The ones where something persists in the tissue and produces a durable structural change. A material that remains and provokes a response is at least consistent with part of the claim. A preparation that is reabsorbed, or a product with no authorisation and no long-term data, is not.
Risks & Limitations
- The word regenerative describes a marketing position rather than an approved class, and no authority approves a material as regenerative.
- Cell and exosome products are generally not approved as cosmetic treatments, and warnings have been issued about advertising them as treatments.
- Most injected cells do not survive in useful numbers, which is the step that a claim of tissue rebuilding depends on.
- An absence of reported harm in an unapproved product is an absence of reporting rather than a finding of safety.
- A point-of-care preparation carries a risk of infection introduced during preparation, because blood handled outside a controlled laboratory is a medium in which bacteria grow.
When to Seek Care
- Redness, warmth, swelling or pain that is increasing rather than settling after a procedure.
- Discharge from an injection site, or a fever — seek prompt clinical assessment.
- Any new and persistent symptom after a procedure, or a change in the treated area that concerns you.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — warnings and guidance on unapproved cell and exosome products
- European Medicines Agency (EMA) and national regulators — advanced therapy classification and guidance
- National Medical Products Administration (NMPA, China) — approved biological products and their indications
- World Health Organization (WHO) — guidance on cell and tissue-based therapies and their oversight
- Cochrane Library — systematic reviews of cell-based and platelet treatments for skin indications
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.